Prevention and Treatment of Cytomegalovirus Infection Through Immunization with Novel CMV-derived Peptides
- Technology Benefits
- Benefits: Potential therapy for CMV infection Potential vaccine for patients that would be at risk for CMV reactivation Features: Novel human and murine CMV- derived peptides capable of stimulating an immune response in subjects having or at risk of having CMV infection Peptides selected for immunogenicity based on available computer-based algorithms Immunogenicity tested in vitro through phenotypical analysis of T cell effectors
- Technology Application
- Cytomegalovirus is the most common congenital infection in the U.S. About 1%-4% of uninfected mothers have primary CMV infection during a pregnancy. 33% of women who became infected with CMV for the first time during pregnancy pass the virus to their unborn babies.
- Detailed Technology Description
- UCSD researchers have developed new human and murine CMV pp65- and ppM83- derived peptides able to stimulate the patients’ immune response for the prevention and therapy of CMV infection. The novel peptides could ameliorate the symptoms of subjects suffering from CMV infection who have failed current treatments, such as ganciclovir therapy. The technology could also be used as a prophylaxis for individuals that would be at risk for CMV reactivation, such as transplant patients who are CMV-positive or have a CMV-positive donor. These peptides can bind a major histocompatibility complex (MHC) class II receptor or a T cell receptor, providing an epitope that induces a proinflammatory immune response in human T cell effectors. The peptides have been selected for their immunogenicity based on available computer-based algorithms.
- Supplementary Information
- Patent Number: US20100111992A1
Application Number: US2008297907A
Inventor: Albani, Salvatore | TTremoulet, Adriana H.
Priority Date: 1 May 2006
Priority Number: US20100111992A1
Application Date: 14 Jan 2010
Publication Date: 6 May 2010
IPC Current: A61K003912 | A61K003512 | C07K000200 | C12N000510 | C12N001511 | C12N001519 | C12N001533 | C12N001585 | C12Q000170
US Class: 4241861 | 4240937 | 435005 | 4353201 | 435325 | 530350 | 530403 | 5360231 | 5360235
Assignee Applicant: The Regents of the University of California
Title: CYTOMEGALOVIRUS PEPTIDES AND METHODS OF USE THEREOF
Usefulness: CYTOMEGALOVIRUS PEPTIDES AND METHODS OF USE THEREOF
Summary: The peptide, composition and method are useful for stimulating an immune response in a subject having or at risk of having CMV infection or for ameliorating or treating clinical signs and/or symptoms associated with CMV infection.
Novelty: New cytomegalovirus (CMV) peptide, useful for ameliorating or treating clinical signs and/or symptoms associated with CMV infection
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Other Disease
- Others
-
State Of Development
Development Status :
This technology is offered exclusively or nonexclusively in the US and/or worldwide territories.Other Information
Researcher:
Dr. Salvatore Albani, MD, Ph.D., formerly at UCSD, has recently joined the University of Arizona College of Medicine as Stephen’s Chair of Rheumatology, director of the Arizona Arthritis Center, and professor of medicine and pediatrics.Related Materials
The Albani Molecular Research Lab
Tech ID/UC Case
19744/2006-074-0
Related Cases
2006-074-0
- *Abstract
-
Although most cytomegalovirus (CMV) infections are silent, meaning that the primary infection does not produce symptoms in healthy individuals, CMV can cause life and sight-threatening disease in people with a weakened immune system. Cellular immunity against CMV is essential for recovery from infection and control of viral latency.
In immunocompromised hosts, this balance between CMV and cellular immunity is lost resulting in virus reactivation. In addition, CMV has emerged in recent years as the most important cause of congenital infection in the developed world, leading to mental retardation and developmental disability of infants infected before birth. There is a need for therapies for patients suffering from CMV infection who have failed current treatments, such as ganciclovir, and for strategies to prevent CMV infection.
- *Principal Investigator
-
Name: Salvatore Albani
Department:
Name: Adriana Tremoulet
Department:
- Country/Region
- USA
